us-abfm MCQ (SBA): CKD Progression Therapy

Instant feedback + full explanation. One question, done properly.

ModerateNephrologyCKD Progression Therapyus-abfmus-abimus-usmle-step-3

A 71-year-old with CKD G3b (eGFR 38 mL/min/1.73 m²) and UACR 450 mg/g has type 2 diabetes and optimized ACE inhibitor therapy. Which additional therapy specifically slows CKD progression?

Educational content. Not a substitute for clinical judgement or local policy.

us-abfm MCQ: CKD Progression Therapy — Answer & Explanation | iatroX